Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases

A. V. Kozyr', A. V. Kolesnikov, E. S. Aleksandrova, L. P. Sashchenko, N. V. Gnuchev, P. V. Favorov, M. A. Kotelnikov, E. I. Iakhnina, Igor Astsaturov, T. B. Prokaeva, Z. S. Alekberova, S. V. Suchkov, A. G. Gabibov

Research output: Contribution to journalArticlepeer-review

103 Scopus citations

Abstract

DNA-hydrolyzing activity of IgG autoantibodies from sera of patients with various types of lymphoproliferative diseases was investigated. The association of DNA-hydrolyzing activity with the antibody (Ab) fraction has been proved by newly developed affinity-capture assay. Study of abzyme incidence in blood tumors and systemic lupus erythematosis (SLE) revealed linkage of anti-DNA Ab catalysts to mature B-cell tumors, and increased probability of DNA-abzymes formation on the background of autoimmune manifestations. These data suggest possible similarity between mechanisms of abzyme formation in SLE and B-cell lymphomas. A new mechanism of formation of DNA-specific catalytic Abs has been proposed based on the increased crossreactivity of polyclonal DNA-abzymes to DNA-depleted nuclear matrix proteins. The possibility of the abzyme production as Ab to the energetically destabilized ground state of the antigen has been discussed. Preliminary results were obtained that indicate the complement-independent cytotoxicity of anti-DNA autoantibodies isolated from blood of patients with SLE and chronic lymphocytic leukemia.

Original languageEnglish
Pages (from-to)45-61
Number of pages17
JournalApplied Biochemistry and Biotechnology
Volume75
Issue number1
DOIs
StatePublished - 1998

Keywords

  • Affinity-capture assay
  • Autoantibody cytotoxicity
  • Chronic lymphocytic leukemia
  • DNA- protein complexes
  • DNA-hydrolyzing antibodies
  • Lymphoproliferative diseases
  • Nuclear matrix

Fingerprint

Dive into the research topics of 'Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases'. Together they form a unique fingerprint.

Cite this